|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administration_guidelines
|
trained healthcare professional
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Lupron
|
|
gptkbp:class
|
hormonal therapy
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
palliative treatment
hormone-sensitive cancers
|
|
gptkbp:condition
|
gptkb:endometriosis
benign prostatic hyperplasia
uterine fibroids
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
hypersensitivity to leuprolide
|
|
gptkbp:dosage_form
|
45 mg
|
|
gptkbp:drug_interactions
|
anticoagulants
CYP450 inducers
|
|
gptkbp:effective_date
|
gptkb:2002
FDA approved
|
|
gptkbp:formulation
|
injectable suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eligard 45 mg
|
|
gptkbp:ingredients
|
gptkb:leuprolide_acetate
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
bone density
hormone levels
blood glucose
|
|
gptkbp:lifespan
|
3 hours
|
|
gptkbp:manufacturer
|
gptkb:Taro_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
gptkb:Hirogen
|
|
gptkbp:patient_education
|
lifestyle modifications
report severe side effects
importance of follow-up appointments
|
|
gptkbp:pharmacokinetics
|
subcutaneous absorption
|
|
gptkbp:price
|
varies by insurance
|
|
gptkbp:rounds
|
urine
|
|
gptkbp:route_of_administration
|
subcutaneous injection
|
|
gptkbp:service_frequency
|
every 6 months
|
|
gptkbp:side_effect
|
gptkb:anemia
gptkb:depression
fatigue
headache
nausea
cardiovascular events
weight gain
osteoporosis
hot flashes
decreased libido
|
|
gptkbp:storage
|
refrigerate
|
|
gptkbp:trade
|
gptkb:Eligard
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:website
|
abdomen
|
|
gptkbp:bfsParent
|
gptkb:Eligard
|
|
gptkbp:bfsLayer
|
6
|